Novo Nordisk expands programme to reach 20,000 children with diabetes in developing countries
- Details
- Category: Novo Nordisk
Today, Novo Nordisk announced a four-year extension of its Changing Diabetes® in Children programme which provides access to diabetes care and free insulin to children with type 1 diabetes in developing countries. The expansion sees five new countries join the programme; Cambodia, Ivory Coast, Myanmar, Senegal and Sudan. By 2020, more than 20,000 children over the course of 11 years will have benefited from the programme.
Merck wins R&D 100 Award for top invention
- Details
- Category: Merck Group
Merck, a leading science and technology company, received a prestigious R&D 100 Award for its Sanger Arrayed Lentiviral CRISPR Libraries - the first of its kind CRISPR libraries. R&D Magazine announced the awards at its 54th Annual R&D 100 Awards Dinner on Nov. 3 in Washington D.C.
Regorafenib from Bayer submitted to health authorities seeking approval in second-line treatment of liver cancer
- Details
- Category: Bayer
Bayer has announced the submission of applications to extend the marketing authorization for its oral multi-kinase inhibitor regorafenib in the U.S., Japan and Europe, for the second line treatment of patients with unresectable hepatocellular carcinoma (HCC). Regorafenib is already approved under the brand name Stivarga® in many countries to treat metastatic colorectal cancer and metastatic gastrointestinal stromal tumors.
New European study highlights differing priorities in physician's therapy goals when treating advanced lung cancer patients
- Details
- Category: Boehringer Ingelheim
Results from a survey analysing the prescribing behaviour of 500 European physicians treating patients with advanced non-small cell lung cancer (NSCLC) have been published in Clinical Lung Cancer. The research examined the primary therapy goal of physicians and their choice of treatment for patients with advanced adenocarcinoma of the lung, after first-line chemotherapy.
Merck invests € 250 million in production value chain in China
- Details
- Category: Merck Group
Merck, a leading science and technology company, today inaugurated its € 170 million Nantong pharmaceutical plant, which is dedicated to producing high-quality pharmaceuticals on China's Essential Drug List. At the inauguration ceremony, Merck also announced a further investment of around € 80 million in a Life Science Center
New study showed that only 55% of people with obesity have received a formal obesity diagnosis
- Details
- Category: Novo Nordisk
Divergent perceptions and attitudes about obesity may jeopardise obesity management outcomes, according to findings from the Awareness, Care & Treatment In Obesity Management (ACTION) study. The findings were presented at Obesity Week 2016, the fourth annual combined congress of the American Society for Metabolic and Bariatric Surgery and The Obesity Society.
Pfizer's Prevenar 13® receives approval for use in infants and children in China
- Details
- Category: Pfizer
Pfizer China announced today that it has received approval from the Chinese Food and Drug Administration (CFDA) to market its pneumococcal 13-valent conjugate vaccine, Prevenar 13®, in China for active immunization for the prevention of invasive diseases (including bacteremic pneumonia, meningitis, septicemia, and bacteremia) caused by Streptococcus pneumoniae (S. Pneumoniae) serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in infants and children aged 6 weeks to 15 months.
More Pharma News ...
- Merck partners with American Cancer Society to address cancer in women
- Novartis wins two prestigious Prix Galien Foundation Awards
- A great place to work, according to Science
- AstraZeneca head and neck cancer trials
- Bristol-Myers Squibb reports third quarter results
- Bayer shows strong performance
- Amgen builds its digital health capabilities through investment in leading digital health incubator